Study of correlation of nitrite levels with malonaldehyde and the prognosis of patients with sickle cell disease on hydroxyurea, Ceará-BRAZIL

Journal of Clinical Laboratory Analysis

Volumn 25, Issue 5, 2011, Pages 369-373

  Gonçalves, Romélia Pinheiro ^a   Elias, Darcielle Bruna Dias ^a   Magalhães, Hemerson Iury Ferreira ^a   de Souza, Jacqueline Holanda ^b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Hemocenter do State of Ceará ^*  (Brazil)

Author keywords

Clinical profile; Hydroxyurea; Malonaldehyde; Nitrite reductases; Sickle cell disease

Indexed keywords

HYDROXYUREA; MALONALDEHYDE; NITRITE;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD VESSEL OCCLUSION; BRAZIL; CHRONIC DISEASE; FEMALE; HEMOLYTIC ANEMIA; HOSPITAL; HUMAN; LEG ULCER; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PROGNOSIS; SERUM; SICKLE CELL ANEMIA; ULCER;

ADULT; ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; BRAZIL; COHORT STUDIES; FEMALE; HUMANS; HYDROXYUREA; LEG ULCER; MALONDIALDEHYDE; NITRITES; OXIDATIVE STRESS; PROGNOSIS;

EID: 80052824602     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20488     Document Type: Article

References (26)

1. Wood KC, Grander DN. Sickle cell disease: Role of reactive oxygen and nitrogen metabolites. Clin Exp Pharmacol 2007;34:926-932.
2. Kaul DK, Liu XD, Xiaoqin Z, Ma L, Hsia CJC, Nagel RL. Inhibition of sickle red cell adhesion and vasooclusion in the microcirculation by antioxidants. Am J Physiol Heart Circ Physiol 2006;291:167-175.
3. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: A systematic review for efficacy and toxicity in children. Pediatrics 2008;122:1332-1342.
4. Gladwin MT, Shelhamer JH, Ognibene FP, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 2002;116:436-444.
5. Cokic VP, Andric SA, Stojikovic SS, Noguchi CT, Schechter AN. Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood 2008;111:1117-1123.
6. Cannalli AA, Franco-Penteado CF, Saad ST, Conran N, Costa FF. Increased adhesive properties of the neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Hematol J 2008;93:605-609.
7. Quinn CT, Shull EP, Ahmed N, Lee NJ, Rogers ZR, Buchanan GR. Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia. Blood 2007;109:40-45.
8. Gizi A, Papassotiriou I, Apostolakou F, et al. Assessment of oxidative stress in patients with sickle cell disease: The glutathione system and the oxidant-antioxidant status. Blood Cells Mol Dis 2011;46:220-225.
9. Clark BE, Thein SL. Molecular diagnosis of haemoglobin disorders. Clin Lab Haematol 2004;26:159-176.
10. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990;186:421-431.
11. Brasil. Ministério da Saúde-manual da anemia falciforme para a população; 2004. p 24.
12. Elagouz M, Jyothi S, Gupta, Sivaprasad S. Sickle cell disease and the eye: Old and new concepts. Surv Ophthalmol 2010;55:359-377.
13. Vichinsky E. New therapies in sickle cell disease. Lancet 2002;360:629-631.
14. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: A state of nitric oxide resistance. Free Radic Biol Med 2008;44:1506-1528.
15. Martins VD, Manfredini V, Peralba MCR, Benfato MS. Alpha-lipoic acid modifies oxidative stress parameters in sickle cell trait subjects and sickle cell patients. Clin Nutr 2009;28:192-197.
16. Fasola F, Adepapo K, Anetor J, Kuti M. Total antioxidants status and some hematological values in sickle cell disease patients in steady state. J Natl Méd Assoc 2007;99:891-894.
17. Rusanova I, Escames G, Cossio G, et al. Oxidative stress status, clinical outcome, and b-globin gene cluster haplotypes in pediatric patients with sickle cell disease. Eur J Haematol 2010;85:529-537.
18. King SB. Nitric oxide production from hydroxyurea. Free Radic Biol Med 2004;37:737-744.
19. Morris CR, Vichinsky EP, Van Warmendam J, et al. Hydroxyurea and arginine therapy: Impact n nitric oxide production in sickle cell disease. J Pediatric Hematol Oncol 2003;25:629-634.
20. Lopez BL, Kreshak AA, Morris CR, Davis-Moon L, Ballas SK, Ma XL. l-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol 2003;120:532-534.
21. Apel K, Hir H. Reactive oxygen species: Metabolism, oxidative stress, and signal transduction. Annu Rev Plant Biol 2004;55:373-399.
22. Cançado RD, Lobo C, Ângulo IL, Araújo PIC, Jesus JA. Protocolos clínico e diretrizes terapêuticas para uso de hidroxiureia na doença falciforme. Rev Bras Hematol Hemoter 2009;31:361-366.
23. Agil A, Sadrzadeh SMH. Hydroxyurea protects erythrocytes against oxidative damage. Redox Rep 2000;5:29-34.
24. Vasconcelos SML, Goulart MOF, Moura JBF, Manfredini V, Benfato MS. Espécies reativas de oxigênio e de nitrogênio, antioxidantes e marcadores de dano oxidativo em sangue humano: Principais métodos analíticos para sua determinação. Quim Nova 2007;30:1323-1338.
25. Mack AK, Kato GJ. Sickle cell disease and nitric oxide: A paradigm shift? Int J Biochem Cell Biol 2006;38:1237-1243.
26. Pelletier MM, Kleinbongard P, Ringwood L, et al. The measurement of blood and plasma nitrite by chemiluminescence: Pitfalls and solutions. Free Radic Biol Med 2006;41:541-548.